Search
for
Sort by
Research 31–60 of 1000+
- Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Review of Baricitinib in the Treatment of Alopecia Areata.
- Baricitinib for the Treatment of Alopecia Areata
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Alopecia areata: from pathophysiology to therapeutic innovation
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- 5PSQ-117 Effectiveness of baricitinib in alopecia areata
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Differential impact of environmental factors on systemic and localized autoimmunity
- Irish dermatologists’ experience with JAK inhibitors in alopecia areata
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review